HC Wainwright Trims Inhibrx Target to $220 After Wider Loss; Shares Fall 6.77%
HC Wainwright cut its INBX price target to $220 from $245 and kept its Buy rating, blaming higher other expenses for a wider quarterly loss. Shares closed at $77.66, down 6.77% from Friday.

HC Wainwright lowered its price target on Inhibrx Biosciences, Inc. (NASDAQ: INBX) to $220 from $245 on Monday, Nov. 16, and kept its Buy rating. The note followed the company's third-quarter results, released after the close on Friday, Nov. 13, at 4:02 p.m. ET. The firm said the quarterly loss was wider than it had forecast.
A trimmed target, a lower stock and an expected equity raise
HC Wainwright kept its Buy rating, saying the company's cash supports several data catalysts through 2027. The firm also said it expects Inhibrx to raise equity. Shares closed Monday at $77.66, down 6.77% from Friday's close, and the note was published before the market opened.
Shares were already sliding before the results
The stock fell before the company reported. Friday's regular session ended at $83.30, down 5.07%. In after-hours trading (the session after the 4:00 p.m. close) it fell another 4.49% to about $79.56. A shelf registration, which lets a company sell securities later, was also filed that evening.
Monday's pre-market session (trading before the 9:30 a.m. open) was quiet. The stock last traded at $81.60 there, up 2.56% from Friday's after-hours close, on volume of 5,696 shares. The regular session opened 3.63% below Friday's close, ranged from $76.50 to $84.71 and ended near the low. Volume was 229,333 shares, against a 10-day average of 241,184. It is not clear what drove the slide after the open.
In after-hours trading Monday, 104 shares changed hands at $77.66, unchanged from the close.
Over the four weeks before the report, the stock peaked at $100.20 on Oct. 22 and bottomed at $66.80 on Oct. 30. It fell 23.38% on Oct. 28 and rose 12.36% on Nov. 3. It then closed lower four sessions in a row, from $91.74 on Nov. 9 to Friday's $83.30.
The loss missed HC Wainwright's estimate on other expenses
Analyst Robert Burns wrote that the loss of $2.46 per share compared with his estimate of $2.14. He attributed the gap mainly to higher-than-anticipated other expenses. R&D spending of $26.0 million and SG&A (selling, general and administrative) expenses of $7.8 million were close to his forecasts of $26.1 million and $7.7 million.
HC Wainwright raised its 2026 loss estimate to $9.22 per share from $8.93. Estimates for the quarter varied across analysts.
Inhibrx has a market value of about $1.23 billion and a float (shares available to trade) of about 10.02 million shares.
What the quarter showed about Inhibrx
According to the company's 8-K filing:
- Net loss was $38.7 million, or $2.46 per share, against $35.3 million, or $2.28, a year earlier.
- Revenue was $2.0 million, from a non-exclusive patent license with Pfizer that carried a $2.0 million upfront payment. The company had no revenue in the third quarter of 2025.
- Cash and cash equivalents were $199.5 million at Sept. 30.
- R&D expense fell to $26.0 million from $28.5 million. General and administrative expense rose to $7.8 million from $5.3 million on pre-commercialization work for ozekibart in chondrosarcoma.
- Other expense rose to $7.0 million from $1.4 million, mainly on interest for a $275.0 million loan balance, up from $100.0 million.
HC Wainwright said the cash could provide an operating runway into the second quarter of 2028.
Catalysts ahead
- Nov. 19-20: the company plans to present updated Phase 1/2 results for ozekibart with irinotecan and temozolomide in refractory Ewing sarcoma at the CTOS meeting in Seoul.
- April 14, 2027: HC Wainwright named this as the date by which the FDA could approve ozekibart in metastatic or unresectable conventional chondrosarcoma. The company said commercial readiness is advancing in line with the review timeline.
- Mid-2027: the company expects an initial readout from the Phase 2 expansion of ordastobart in HPV-positive head and neck cancer, and initial Phase 1/2 results in perioperative non-small cell lung cancer.
Bottom line
HC Wainwright cut its target but kept its Buy rating, and it traces the wider loss to other expenses rather than R&D or SG&A. The stock was already down about 5% on Friday before the results and ended Monday below its pre-market level. The Ewing sarcoma presentation on Nov. 19-20 is the next company event.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




